
HeartFlow Stock
Medical Technology Company
Sign up today and learn more about HeartFlow Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About HeartFlow Stock
HeartFlow is a medical technology company that provides non-invasive coronary artery disease detection services. The company's main product is HeartFlow FFR Analysis, which aims to help a physician evaluate whether a patient has significant coronary artery disease. HeartFlow FFRCT Analysis uses a CT scan ordered by a physician to generate a 3D model of the patient's coronary arteries. The analysis aims to calculate the amount of blockage in the arteries and the limited blood flow. The HeartFlow FFRCT Analysis is commercially available in the United States, Canada, Europe, and Japan.
Christopher K. Zarins and Charles Anthony Taylor founded Cardiovascular Simulation in 2007 which became HeartFlow in May 2009. The company is headquartered in Redwood City, California. Notable investors include Panorama Point Partners, Capricorn Investment Group, and Baillie Gifford.
Investors
Capricorn Investment Group
HeartFlow, Aspiration, QuantumScape, Innovium, Diamond Foundry, Kinestral Technologies
Emergent Medical Partners
LifeForce Capital
Cityblock Health, HeartFlow, One Medical, Clover Health, Grand Rounds Health, Vineti, Verge Genomics
Martis Capital
Rancilio Cube
Wellington Management
Swiggy, Scopely, Cityblock Health, Attentive, HeartFlow, Skims, Urban Company, Greenlight, Guild Education, Omada Health
Funding History
July 2009 | $2.0M |
---|---|
August 2010 | $6.9M |
August 2010 | $10.1M |
December 2011 | $105M |
January 2015 | $111M |
November 2017 | $305M |
March 2023 | $41.0M |
March 2023 | $175M |
Management
Chief Executive Officer
John Farquhar
Chief Scientific Officer
Charles Anthony Taylor
Press
massdevice - Mar, 1 2022
HeartFlow announces new CEOfiercebiotech - Feb, 7 2022
HeartFlow halts SPAC deal, citing 'current unfavorable market conditions'bizjournals - Feb, 5 2022
HeartFlow cancels plans to go public in SPAC mergermarketwatch - Feb, 4 2022
HeartFlow and Blank-Check Co. Agree to Terminate Deal Due to Market Conditionsglobenewswire - Nov, 15 2021
HeartFlow Appoints Dr. Wayne J. Riley to its Board of Directorsbiospace - Sep, 2 2021
HeartFlow Announces Enrollment of First Three Patients in FUSION Trialmassdevice - Aug, 4 2021
HeartFlow appoints former Medtronic executive as COObiospace - Jul, 16 2021
Medtech HeartFlow Joins SPAC Movement, Plans to List on NYSEbioworld - Jul, 15 2021
Heartflow charts IPO via $2.4B SPAC dealBusinessWire - Apr, 6 2021
New Medicare Local Coverage Determinations Published for the HeartFlow Analysisneurons - Feb, 16 2021
AI vs heart disease: NHS and Heartflow partner on cardiac diagnosticsBioWorld - Jan, 31 2020
Heartflow eyes two more MACs, but rates still a source of dragtechradar - Dec, 10 2019
Virtually modelling surgery in real-time: a Q&A with HeartFlowMedical Device - Oct, 24 2019
HeartFlow Analysis: a better way to diagnose heart disease?businesswire - Sep, 12 2019
HeartFlow Announces FDA Clearance for HeartFlow Plannermassdevice - Jun, 17 2019
HeartFlow adds another $65mbioportfolio - May, 23 2019
Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Diseasecomputerworlduk - Feb, 21 2019
Birmingham City Hospital turns to HeartFlow’s AI software to fight CHDmassdevice - Feb, 8 2019
HeartFlow publishes findings from consumer survey3ders.org (blog) - Feb, 16 2018
HeartFlow raises $240M to commercialize 3D heart model diagnosis technologyMass Device - Dec, 5 2017
HeartFlow stakes $90m step toward $150m Series Efiercemedicaldevices - Feb, 13 2015
HeartFlow raising $46M after recent FDA nod for noninvasive coronary artery disease testEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase